EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition

Joseph G Matous, Jeremy P Snook, Nico A Contreras, Andrew G Ramstead, Krystal R Charley, Elizabeth M Kolawole, Jacob N Kisiolek, Kaitlyn A Flint, Ashleigh J Soedel, Breyana Robinson, Anaiya B Mendoza, Yohichi Kumaki und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Joseph G Matous und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 6, Immune Checkpoint Inhibitors, Autoantigens, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, DOD Peer Reviewed Cancer Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The presence of activated CD8 T cells in the tumor microenvironment is correlated with an effective immune response to immune checkpoint inhibitor (ICI) therapy. However, ICI predominantly targets high-affinity T cells, which may be less abundant in tumors with few neoantigens. Targeting the intracellular phosphatase Src homology region 2 domain-containing phosphatase-1 (Shp-1) in combination with ICI lowers the T cell activation threshold and enhances the ability of low-affinity T cells to mount a productive antitumor response.

Methods

In this study, we sought to determine whether temporal inhibition of Shp-1 during active tumor growth could rescue the activity of low-affinity T cells specific for endogenous self-antigens. To address this question, we implanted Yale University Mouse Melanoma (YUMM) tumor cell lines into WT mice and, on tumor establishment, administered an inhibitor of Shp-1 (TPI-1) with or without ICI treatment. We analyzed treatment-dependent changes in the immune infiltrate in the tumor via flow cytometry, major histocompatibility complex (MHC) tetramer-mediated detection of tyrosinase-related protein 2 (TRP-2) 180–188 -specific T cells and a micropipette-based two-dimensional affinity assay to measure the T cell receptor (TCR) affinity.

Results

Administration of ICI and a Shp-1 inhibitor to mice with established YUMM tumors, but neither agent alone, resulted in a significant delay in tumor growth and an increased frequency of CD8 tumor-infiltrating T cells with enhanced effector and reduced exhaustion characteristics. In particular, combined treatment increased the frequency of CD8 T cells specific for the MHC Class I-restricted tumor self-antigen TRP-2 180–188 . We found that the increase in effector T cells was almost entirely due to an increase in T cells with very low TCR affinity.

Conclusions

We conclude that approaches for altering TCR signaling threshold are effective in enhancing the antitumor response of low-affinity T cells specific for endogenous self-antigens in settings of ICI resistance and/or where neoantigens are not available to drive antitumor responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 6Immune Checkpoint InhibitorsAutoantigensMelanomaAnimalsMiceHumansCell Line, TumorCD8-Positive T-LymphocytesTumor MicroenvironmentFemaleDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyMelanomaT cellT cell Receptor - TCR

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 6Immune Checkpoint InhibitorsAutoantigensPtpn6 protein, mouse

Autor:innen und Institutionen

  • Department of Pathology, The University of Utah, Salt Lake City, Utah, USA.
  • Huntsman Cancer Institute, Salt Lake City, Utah, USA.
  • North Carolina Agricultural and Technical State University, Greensboro, North Carolina, USA.
  • Spelman College, Atlanta, Georgia, USA.
  • Department of Pathology, The University of Utah, Salt Lake City, Utah, USA matthew.williams@path.utah.edu.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • DOD Peer Reviewed Cancer Research Program

Zitieren

APA

Matous, J. G., Snook, J. P., Contreras, N. A., Ramstead, A. G., Charley, K. R., Kolawole, E. M., Kisiolek, J. N., Flint, K. A., Soedel, A. J., Robinson, B., Mendoza, A. B., Kumaki, Y., Evavold, B. D., & Williams, M. A. (2025). Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010879

Vancouver

Matous JG, Snook JP, Contreras NA, Ramstead AG, Charley KR, Kolawole EM, et al. Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010879

BibTeX
@article{Matous2025,
  author = {Matous, Joseph G and Snook, Jeremy P and Contreras, Nico A and Ramstead, Andrew G and Charley, Krystal R and Kolawole, Elizabeth M and Kisiolek, Jacob N and Flint, Kaitlyn A and Soedel, Ashleigh J and Robinson, Breyana and Mendoza, Anaiya B and Kumaki, Yohichi and Evavold, Brian D and Williams, Matthew A},
  title = {Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010879}
}
Kostenlos starten →